Please complete Pre-test

Chapter 1 of 1



Expected time to complete this activity as designed: 30 minutes

There are no fees for participating in or receiving credit for this online activity.

Program Overview

In this activity, Dr. Sergio Giralt discusses the role of transplant in light of the new agents that are now available, which patients should be considered for stem cell transplant, and the barriers and challenges that confront patients and their families as they face important treatment decisions.

Target Audience

This activity is designed for multidisciplinary healthcare providers in the community setting, including hematologists, oncologists, pharmacists and other allied healthcare professionals who provide care to patients with acute myeloid leukemia.

Learning Objectives

Upon completion of this educational activity, participants should be able to:

  • Summarize the role of transplant in light of the new novel agents now available
  • Describe which patients should be considered for stem cell transplant
  • Outline common barriers and challenges confronted in transplant as an option for treatment
  • Review options to optimize chemotherapy prior to transplant


Transplant as an Option for Patients with AML: Current Standard of Care – Sergio A. Giralt, MD

Instructions for Participation and Credit

This activity is eligible for credit through March 12, 2021. After this date, this activity will expire and no further credit will be awarded.

  1. Read the target audience, learning objectives, and faculty disclosures.
  2. You may be asked to complete a short pre-test before accessing the educational content. This must be completed in order to move forward in the activity.
  3. Complete the educational content as designed.
  4. Complete the post-test. To receive a certificate, you must receive a passing score of 70%.
  5. Complete the activity evaluation survey to provide feedback and information useful for future programming.
  6. Certificates for CME may be printed immediately after successfully completing the post-test and activity evaluation. Pharmacist credit will be uploaded to CPE Monitor 4 weeks following receipt of a completed, qualified form.

Faculty Biography

Sergio A. Giralt, MD
Chief Attending, BMT Service
Memorial Sloan Kettering Cancer Center
Professor of Medicine
Weill Cornell Medical College
New York, New York

Dr. Sergio Giralt received his medical degree from Universidad Central de Venezuela. He completed his residency at Good Samaritan Hospital and his fellowship at The University of Texas MD Anderson Cancer Center. In addition to his positions at Memorial Sloan Kettering Cancer Center, Dr. Giralt is Professor of Medicine at Weill Cornell Medical College and the Melvin Berlin Family Chair in Myeloma Research.

Dr. Giralt is an active member of several professional societies, including the American Society of Hematology, the American Society of Clinical Oncology, the North American Society of Blood and Bone Marrow Transplantation (ASBMT), the International Society of Hematotherapy and Graft Engineering, and the Gerontological Society of America. He previously served as chairperson on the executive board of the Center for International Blood and Marrow Transplant Research and the steering committee of the Blood and Marrow Transplant Clinical Trials Network, and he is past president of ASBMT.

A board-certified hematologist/oncologist whose clinical practice and research focus on stem cell transplantation for patients with blood disorders, Dr. Giralt and colleagues pioneered the use of reduced-intensity conditioning regimens for older/more debilitated patients with blood cancers. Currently, Dr. Giralt’s research is examining the use of T-cell depletion techniques to dramatically reduce the risk of graft-versus-host disease. He has published and presented extensively on these topics. Additionally, Dr. Giralt has served as the principal investigator for a number of clinical trials that examine new treatment approaches for multiple myeloma and other blood cancers that aim to reduce symptom burden and improve treatment tolerability.

If you have any questions or concerns regarding this activity, please contact MediCom Worldwide, Inc. at 1-800-408-4242 or email us at

Provided by MediCom Worldwide, Inc.
This activity is supported by educational grants from Celgene Corporation and Helsinn.

©2020 MediCom Worldwide, Inc., 101 Washington St., Morrisville, PA 19067, 800-408-4242.
No portion of this material may be copied or duplicated without the expressed permission of MediCom Worldwide, Inc.

Accreditation Statement: MediCom Worldwide, Inc. is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.
Designation Statement: MediCom Worldwide, Inc. designates this enduring material for a maximum of 0.50 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
MediCom Worldwide, Inc. is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education. This activity is acceptable for 0.50 contact hours of Continuing Education Credit. Universal Activity Number: 827-0000-20-011-H01-P. Knowledge-based CPE activity.

In order for CPE Monitor to authenticate credit, pharmacists/technicians must provide their e-Profile ID number from NABP and date of birth (in MMDD format) when claiming credit for a CPE program.

International Pharmacy Preceptors and Canadian Pharmacists: If you are in need of e-Profile ID to participate in an ACPE approved activity, please contact NABP customer service for further assistance as special handling is necessary. NABP customer service can be reached at (847) 391-4406.


As an organization accredited by the Accreditation Council for Continuing Medical Education (ACCME), Accreditation Council for Pharmacy Education (ACPE) and California State Board of Registered Nursing, MediCom Worldwide, Inc. requires everyone who is in a position to control the content of an educational activity to disclose all relevant financial relationships with any commercial interest. The ACCME defines “relevant financial relationships” as financial relationships in any amount, occurring within the past 12 months, including financial relationships of a spouse or life partner, that could create a conflict of interest. Accordingly, the following disclosures were made.

Faculty Disclosure

Dr. Sergio Giralt has received honoraria related to formal advisory activities from Actinium Pharmaceuticals, Inc., Amgen Inc., Celgene Corporation, Janssen Pharmaceuticals, Inc., JAZZ Pharmaceutical plc, Johnson & Johnson Services, Inc., Kite Pharma, Novartis AG, Spectrum Pharmaceuticals, Inc., and Takeda Oncology. He has received grant support related to research activities from Actinium Pharmaceuticals, Amgen, Celgene, Johnson & Johnson, Miltenyi Biotec, Omeros Corporation, and Takeda Oncology.

Planning Committee Disclosures

The individuals listed below from MediCom Worldwide, Inc. reported the following for this activity: Andrea Mathis, Project Manager, and Joan Meyer, RN, MHA, Executive Director, have no relevant financial relationships.

Peer Reviewer Disclosure

In accordance with MediCom Worldwide, Inc. policy, all content is reviewed by external independent peer reviewers for balance, objectivity and commercial bias. The peer reviewers have no relevant financial relationships to disclose.